Brief: Actinium Pharmaceuticals Presents Preclinical Data Related To Her3 Targeted Radiotherapy
11/04/2022 12:54
April 11 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS PRESENTS PRECLINICAL DATA AT AACR
SHOWING HER3 TARGETED RADIOTHERAPY COMBINED WITH THE CD47
IMMUNOTHERAPY MAGROLIMAB INCREASES THE ANTI-TUMOR EFFECT
Source text for Eikon: ID:nPn3DCl2Ja
Further company coverage: ATNM.A
((reuters.briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities